With a greater number of patients being initiated on sodium-glucose cotransporter 2 inhibitors (SGLT2i), healthcare team members may receive more questions related to management of potential adverse effects of these agents, including genital mycotic infections.
The Voice of the Nurse Practitioner® continues to resonate on Capitol Hill. Since the NP Health Policy Conference this past February, we have seen an uptick in cosponsors for important NP legislation which can affect CDE practice, as well.
On January 28th, in both chambers, the Promoting Access to Diabetic Shoes Act was introduced. Representatives Earl Blumenauer (D-OR) and Tom Reed (R-NY) and Senators Sherrod Brown (D-OH) and Susan Collins (R-ME) are continuing to champion this legislation.